Sofosbuvir/Velpatasvir (Epclusa®) chronic hepatitis C virus (HCV) – pangenotypic

Assessment Status Rapid review complete
Drug Sofosbuvir/velpatasvir
Brand Epclusa®
Indication For the treatment of chronic hepatitis C virus (HCV) infection in adults. This indication covers all genotypes (GT1, 2, 3, 4, 5 and 6) i.e. pangenotypic.
Assessment Process
Rapid review commissioned 05/09/2017
Rapid review completed 19/10/2017
Rapid review outcome  Full pharmacoeconomic assessment not recommended